Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 416 Lymphoma 406 Lymphoma, Non-Hodgkin 344 Leukemia, Lymphocytic, Chronic, B-Cell 313 Lymphoma, Follicular 301 Lymphoma, Mantle-Cell 226 Lymphoma, B-Cell, Marginal Zone 161 Leukemia 119 Lymphoma, B-Cell 112 Burkitt Lymphoma 110 Waldenstrom Macroglobulinemia 99 Precursor Cell Lymphoblastic Leukemia-Lymphoma 90 Recurrence 85 Hodgkin Disease 60 Lymphoma, Large-Cell, Immunoblastic 57 Neoplasms 39 Multiple Myeloma 26 Lymphoma, Large-Cell, Anaplastic 26 Myelodysplastic Syndromes 25 Leukemia, Myeloid, Acute 24 Hematologic Neoplasms 22 Dendritic Cell Sarcoma, Interdigitating 22 Leukemia, Hairy Cell 20 Intraocular Lymphoma 17 Leukemia, Prolymphocytic 16 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14 Lymphoma, T-Cell 14 Neoplasms, Plasma Cell 13 Hematologic Diseases 13 Lymphoproliferative Disorders 12

Interventions

ofatumumab 1 ocrelizumab 1 obinutuzumab 1 ibritumomab tiuxetan 1 Rituximab 1 Paclitaxel 1 Diphenhydramine 1 Cetirizine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Oncology Patients Receiving Chemotherapy × Rituximab × Clear all

NCT04189588 2023-10-06

versus

TerSera Therapeutics LLC

Phase 2 Completed

34 enrolled 11 charts

Oncology Patients Receiving Chemotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡